Login / Signup

Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in patient during pregnancy.

Farzan KianersiHeshmatollah GhanbariZahra Naderi BeniAfsaneh Naderi Beni
Published in: Journal of drug assessment (2021)
Use of intravitreal anti-VEGF by pregnant woman may only be justified if the potential benefit outweighs the potential risk to the fetus and only if clearly needed. Intravitreal bevacizumab during pregnancy in women with a history of miscarriage should be used with caution.
Keyphrases
  • vascular endothelial growth factor
  • endothelial cells
  • case report
  • pregnant women
  • human health
  • risk assessment
  • metastatic colorectal cancer